B W Grinnell1, D Joyce. 1. Division of Research Technology, Lilly Corporate Center, Indianapolis, IN 46285, USA. grinnell@lilly.com
Abstract
OBJECTIVE: To review the mechanisms of action and rationale for the use of recombinant human activated protein C in the treatment of severe sepsis. Specifically, we focus on the mechanisms of action in the protein C pathway that converge to modulate the pathophysiology of severe inflammatory disease and sepsis. This analysis includes a discussion of the role of activated protein C in directly modulating cell system biology, independent of antithrombotic activity. DATA SOURCES/STUDY SELECTION: Published research and review articles relating to the protein C pathway, recombinant human protein C, and the role of protein C in sepsis. Data were also derived from broad gene profiling in model systems of endothelial dysfunction. DATA EXTRACTION AND SYNTHESIS: Relevant studies were included to support discussion of the unique mechanistic aspect of protein C and its role in the pathogenesis of severe sepsis. We discuss the potential of activated protein C as a unique system modulator for the treatment of severe sepsis and other systemic inflammatory responses that result in microvascular coagulopathy, endothelial dysfunction, and vascular bed failure. CONCLUSIONS: The protein C pathway plays a unique role in modulating vascular function. As an antithrombotic/profibrinolytic agent, it plays a clear role in maintaining vascular patency. Moreover, it has anti-inflammatory properties and appears to play a unique role as an antiapoptotic and endothelial cell survival factor. In states of systemic inflammatory activation, loss of protein C due to consumptive processes results in a compromised ability to modulate coagulation as well as inflammatory and cell survival functions. This compromise leads to vascular dysfunction, end-organ failure, and death. Replacement with recombinant human activated protein C offers a system-modulating approach to improved outcome.
OBJECTIVE: To review the mechanisms of action and rationale for the use of recombinant human activated protein C in the treatment of severe sepsis. Specifically, we focus on the mechanisms of action in the protein C pathway that converge to modulate the pathophysiology of severe inflammatory disease and sepsis. This analysis includes a discussion of the role of activated protein C in directly modulating cell system biology, independent of antithrombotic activity. DATA SOURCES/STUDY SELECTION: Published research and review articles relating to the protein C pathway, recombinant humanprotein C, and the role of protein C in sepsis. Data were also derived from broad gene profiling in model systems of endothelial dysfunction. DATA EXTRACTION AND SYNTHESIS: Relevant studies were included to support discussion of the unique mechanistic aspect of protein C and its role in the pathogenesis of severe sepsis. We discuss the potential of activated protein C as a unique system modulator for the treatment of severe sepsis and other systemic inflammatory responses that result in microvascular coagulopathy, endothelial dysfunction, and vascular bed failure. CONCLUSIONS: The protein C pathway plays a unique role in modulating vascular function. As an antithrombotic/profibrinolytic agent, it plays a clear role in maintaining vascular patency. Moreover, it has anti-inflammatory properties and appears to play a unique role as an antiapoptotic and endothelial cell survival factor. In states of systemic inflammatory activation, loss of protein C due to consumptive processes results in a compromised ability to modulate coagulation as well as inflammatory and cell survival functions. This compromise leads to vascular dysfunction, end-organ failure, and death. Replacement with recombinant human activated protein C offers a system-modulating approach to improved outcome.
Authors: Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan Journal: J Transl Med Date: 2011-03-04 Impact factor: 5.531
Authors: Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent Journal: Intensive Care Med Date: 2003-04-24 Impact factor: 17.440
Authors: Akanksha Gupta; Bruce Gerlitz; Mark A Richardson; Christopher Bull; David T Berg; Samreen Syed; Elizabeth J Galbreath; Barbara A Swanson; Bryan E Jones; Brian W Grinnell Journal: J Am Soc Nephrol Date: 2008-12-17 Impact factor: 10.121
Authors: R Pathak; L Shao; D Zhou; M Hauer-Jensen; S M Chafekar; W Feng; U Ponnappan; L M Fink Journal: J Thromb Haemost Date: 2014-08-11 Impact factor: 5.824
Authors: Madeline Betancourt; Peggy S McKinnon; R Michael Massanari; Salmaan Kanji; David Bach; John W Devlin Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981
Authors: David T Berg; Bruce Gerlitz; Ganesh R Sharma; Mark A Richardson; Eddie J Stephens; Renee L Grubbs; Kimberly C Holmes; Kelly Fynboe; Dominick Montani; Martin S Cramer; Steven D Engle; Joseph A Jakubowski; Josef G Heuer; Brian W Grinnell Journal: Clin Vaccine Immunol Date: 2006-03